$7.12
+7.55%Oct 28, 2026, 12:30 UTC
Envoy Medical, Inc. announced that its third-quarter 2026 earnings conference call will be held at 8:00 a.m. ET on November 5, with financial results to be released before market open.
Source:Oct 27, 2026, 12:30 UTC
Envoy Medical, Inc. announced that it will report its third-quarter 2026 financial results on November 5, 2026.
Source:Oct 22, 2026, 12:30 UTC
Envoy Medical announced a 1-for-10 reverse stock split of its outstanding Class A common stock, effective October 26, 2026.
Source:Oct 20, 2026, 12:30 UTC
Envoy Medical, Inc. announced that its pivotal clinical trial of the investigational Acclaim cochlear implant surpassed the six-month follow-up milestone, halfway through the final data-collection stage.
Source:Aug 27, 2026, 00:00 UTC
Envoy Medical, Inc. appointed Robert Potashnick as Chief Accounting Officer and Vice President of Finance, effective August 24, 2026.
Aug 10, 2026, 12:00 UTC
Envoy Medical reported financial results for the second quarter ended June 30, 2026, on August 10, 2026.
Source:Jul 21, 2026, 13:17 UTC
Envoy Medical announced that all 56 patients in its pivotal clinical trial for the Acclaim cochlear implant have passed the three-month visit milestone.
Source:Jun 30, 2026, 12:30 UTC
Envoy Medical submitted the first module of its Modular Premarket Approval application to the FDA for its breakthrough-designated hearing device.
Jun 25, 2026, 12:30 UTC
Envoy Medical terminated its at-the-market equity facility effective June 24, 2026.
Source:Jun 25, 2026, 00:00 UTC
Envoy Medical, Inc. appointed Brent Lucas as Chief Executive Officer effective June 19, 2026, with compensation including a base salary of $420,000, a cash bonus target of $105,000, and equity grants of stock options and restricted stock units.